Intercept Downgraded To Sell From Neutral At Goldman Sachs
August 20, 2021 at 08:12 AM EDT
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell from Neutral with a price target of $10, down from $17, implying a 30% downside.
